This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Fidus has outperformed most BDCs when it comes to NAV per share growth, but declined during the recent quarter with realized losses mostly due to the exits of two investments.
AIY AINV HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ HRZN MCV CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC
I have been making purchases of 'higher quality' BDCs this year including GBDC due to consistent dividend coverage, NAV per share growth, and special dividends, delivering higher returns to shareholders.
AIY AINV HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX GSBD HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ HRZN MCV CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC
Like income? If you’re reading this, then you likely do. And odds are good you’re more than a little familiar with the usual suspects … utilities stocks like Southern Co (NYSE:SO), or diversified healthcare giant Pfizer (NYSE:PFE). The former is recession proof, while the latter always seems able to find a market by constantly reinventing its drug portfolio, making them a couple of the best income-producing assets the market has to offer.
SOJA SO NLSN OAK HTGX HTGY IRM HTGZ HTGC PFE CVA OUT CWB
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) incurred a loss of $1.33 per share for the second quarter of 2018, wider than the Zacks Consensus Estimate of a loss of $1.28 but narrower than the year-ago quarter’s loss of $2.18.
HTGZ MACK OAS GILD HTGC ILMN HTGX HTGY
2018-08-07 seekingalpha - 6
Good morning, ladies and gentlemen. Welcome to the TransEnterix Second Quarter's Financial and Operating Results Conference Call. As a reminder, this conference call is webcast live and recorded.
HTGZ HTGC TRXC HTGX HTGY
Good morning and welcome to the Merrimack Pharmaceuticals Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open up the call for your questions.
HTGZ MACK HTGC HTGX HTGY
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is a Cambridge, MA-based development-stage biopharmaceutical company focused on developing innovative therapies in combination with companion diagnostics for the treatment of cancer.
HTGZ MACK AMT HTGC NHI HTGX BCRX HTGY GTLS
My portfolio has been in transition since 2015, moving further towards a high-yield income strategy, and away from individual stocks and their single-issue risk in favor of the diversification offered by funds – mainly closed-end funds (CEFs) and ETFs. The original portfolio already included higher-yield positions such as Omega Healthcare Investors (OHI), Hercules Capital (HTGC), Main Street Capital (MAIN), Starwood Property Trust (STWD), and Gladstone Investment (GAIN), and both Hercules and Starwood have survived the transition.
ARCC CIK MAIN GAIN GAINM GADDP HTGX STWD.WI HTGY HTGZ ARU MSCA.CL UTF MSCA HTGC STWD OHI
MRCC reports Q2 2018 results this week and this article discusses what investors should be looking for including sign of improvement in two of its portfolio investments.
CLA MCQ TCAP KAP MRCC MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC PSEC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB
Shares of Hercules Capital, Inc.’s (HTGC - Free Report) gained 3.3% following the release of second-quarter 2018 results after the markets closed. Adjusted net investment income of 29 cents per share beat the Zacks Consensus Estimate by a penny. However, the figure was 6.5% below the year-ago quarter level. Results reflected higher revenues, growth in investment portfolio and a rise in net asset value.
HTGZ CFIN GARS CY CIWV FSIC HTGC TCPC PF HTGX HTGY
Good day, ladies and gentlemen, and welcome to the Hercules Capital Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded.
HTGZ UBNC HTGC HTGX HTGY
2018-08-01 globenewswire - 1
Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2018 were $46.0 million, compared with $88.1 million as of December 31, 2017. In June 2018, Edge paid down its entire outstanding debt under the Amended Loan Agreement entered into August 2016 with Hercules Capital, Inc. In the second quarter, Edge substantially reduced its scope of operations, including the size of its workforce, in order to preserve its cash resources.
HTGZ EDGE HTGC HTGX HTGY
In June 2018, NMFC held a special meeting and shareholders approved the company becoming subject to a minimum asset coverage ratio of 150%, permitting the company to double its leverage.
CLA MCQ TCAP KAP MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA EDMCQ MCC TCRX ARCC HCAPL EDMC GBDC FDUS MAIN TCC TCPC TCRD TCRZ PSEC HTGX NMFC TSLF HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET